Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer Full Text
The Oncologist, 04/25/2012
O'Shaughnessy JA et al. – First–line capecitabine monotherapy has a favorable safety profile, lacking myelosuppression and alopecia, and does not compromise the administration of further lines of chemotherapy. Capecitabine is suitable for long–term administration without the cumulative toxicity that can limit the prolonged use of other chemotherapy agents.